CER Daily Newsfeed

The Comparative Effectiveness Research Daily Newsfeed®, known for short as the CER Daily Newsfeed®, offers the latest news, research and related information on comparative effectiveness research, real-world data and evidence, value assessment and other important health care topics. 

News from Wednesday, December 10, 2025

Articles

Ketamine Not a Better Anesthetic for Intubation of Critically Ill Patients

(12/9, Crystal Phend, Medpage Today) reports “For tracheal intubation anesthesia in critically ill patients, ketamine didn't improve survival compared with etomidate, a pragmatic clinical trial showed...Large observational studies had supported lower mortality risk in this setting with ketamine compared with etomidate, although trials were inconclusive.” Full

Press Releases

Sedative Choice Could Improve Outcomes for Breathing Tube Patients

(12/10, Vanderbilt University Medical Center Press Release) “Doctors treating seriously ill patients in an emergency setting may want to give the sedative etomidate, rather than ketamine, while placing a breathing tube, according to a randomized trial published in the New England Journal of Medicine...‘Studies like RSI are critically important to understand the treatments that patients are already receiving and to ensure that patients receive the treatments that will result in the best outcomes,’ [lead author Jonathan Casey, MD] said.” Full

Journals

Comparative Effectiveness and Safety of Systemic Therapies for Treatment-Naïve, PD-L1 Expression< 1% Advanced NSCLC: A Systematic Review and Network Meta-Analysis

Mengyun Zhou, et al.

November 30, 2025, Translational Lung Cancer Research

PubMed

Alectinib Versus Crizotinib as the First-Line Treatment in Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: A Chinese Real-World Cohort Study

Haoran Zhang, et al.

November 30, 2025, Translational Lung Cancer Research

PubMed

Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults

Jonathan D. Casey, M.D., et al.

December 9, 2025, The New England Journal of Medicine

NEJM

Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World Survival and Safety Outcomes

Ren-Hua Ye, et al.

December 9, 2025, JCO Oncology Practice

PubMed

Efficacy and Safety of Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Comprehensive Network Meta-Analysis Including Final ARANOTE Data

Neal Shore, et al.

December 9, 2025, Prostate Cancer and Prostatic Diseases

PubMed

Reports

How will a Rebate Model Impact Cash Flow for Price Negotiated Drugs in Medicare Part D?

December 9, 2025

IQVIA